Tizona Therapeutics
Melissa Sahu is a Principal Scientist at Tizona Therapeutics, Inc., leading a protein sciences group since 2021. Prior to this role, Melissa served as a Scientist at CytomX Therapeutics from 2019 to 2021, where responsibilities included purifying antibodies and developing protein expression methods. Melissa's experience also includes a position as Specialist II at the University of California, San Francisco, focusing on antibody pipeline work, and a Graduate Researcher role at Brandeis University, where research included protein characterization and molecular biology. Education includes a Ph.D. in Biochemistry and Biophysics from Brandeis University and a B.S. in Biochemistry from Simmons University. Additionally, Melissa has interned at Novartis Institutes for BioMedical Research, engaged in protein crystallography, and held teaching and outreach roles in green chemistry education.